This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXMPEE6C0AD_M.jpg
Investing.com – Johnson & Johnson stock (NYSE:JNJ) rose by 0.5% in Wednesday’s trading as the Food and Drug Administration said the company’s booster shot against Covid-19 helped boost immune response.
The regulators cautioned that data was limited and they relied on the company’s own analysis for some of the findings, rather than conducting their own study.
The regulator’s view comes in response to the company’s request for authorization of its booster dose.
So far, the Pfizer (NYSE:PFE)-BioNTech (NASDAQ:BNTX) booster is the only to have been approved for administering to those above 60 and other high-risk people.
Along with J&J’s request, the FDA has before it a request from Moderna (NASDAQ:MRNA) for its booster dose.
The J&J shot is the only one in the U.S. carrying a single-dose application. All others are two-dose vaccines.
J&J recommends that a booster be given six months after the initial shot, though it could be given as early as two months also after the first.
